Canakinumab in SCA, antigen-specific donor T-cells to prevent post-transplant relapse in ALL, and nasopharyngeal mucosal immunity defects in transplanted SCID patients

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Reacting to Islamic Apologists | GodLogic | Last Call Ep. 33 34 min · 24 Sep 2026 · Pints With Aquinas

Bond bombshell 22 min · 24 Sep 2026 · Unhedged

Do you have the correct time? 29 min · 24 Sep 2026 · BBC Inside Science

The High Schools Going All-In on AI 20 min · 24 Sep 2026 · The Journal.

Rosa Parks and the Montgomery Bus Boycott: Fighting to End Segregation 3h 6m · 24 Sep 2026 · Sleepy History

TNB Tech Minute: OpenAI Agents Attempt to Hack University and Government Websites 3 min · 24 Sep 2026 · WSJ Tech News Briefing

Report any issue

Source

Recorded28 Apr 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742089

Show notes

In this week’s episode, we’ll discuss the efficacy of canakinumab in children and young adults with sickle cell anemia, learn more about the use of donor-derived multiple leukemia antigen specific T-cell therapy to prevent relapse in post-transplant patients with ALL, and discuss the defects in nasopharyngeal mucosal immunity in patients with severe combined immunodeficiency after hematopoietic stem cell transplantation.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in